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Overall, 525 (55%), 420 (44%), 944 (99%), 948 
(100%), and no strains from Dhaka and 186 
(54%), 165 (48%), 332 (97%), 343 (100%), and 
no strains from Matlab were resistant to tetra-
cycline, erythromycin, trimethoprim-sulpha-
methoxazole, furazolidone, and ciprofloxacin 
respectively. Prior to October 2004, most strains 
were resistant to trimethoprim-sulphamethoxa-
zole and furazolidone but were uniformly sen-
sitive to tetracycline, erythromycin, and cipro-
floxacin. 
The first multidrug-resistant strains of V. cholerae 
(strains resistant to furazolidone, trimethoprim-
sulphamethoxazole, tetracycline, and erythro-
mycin) were observed in Matlab in October 
2004 among the Ogawa serotype, and the iso-
lation of such strains increased dramatically to 
reach 100% by February 2005. In Dhaka, the 
multidrug-resistant strains appeared one month 
later in November 2004 among both Ogawa 
(13%) and Inaba (5%) strains of V. cholerae, and 
by February 2005, all the Ogawa strains demon-
strated the multidrug-resistant phenoytpe. By 
March 2005, nearly all the El Tor Ogawa isolates, 
5 of 6 (83%) at the Matlab Hospital, and 43 of 45 
(96%) at the Dhaka Hospital were multidrug-re-
sistant. The figure shows the resistance patterns 
of V. cholerae in Dhaka and Matlab by month 
and site. 
Based on the multidrug-resistant phenotype, it 
appeared that there were two or more clones of 
V. cholerae O1 in circulation at different time 
points, and we are in the process of understand-
ing the clonality by subjecting representative 
strains to molecular typing analysis. We deter-
mined antimicrobial susceptibility using both 
disc-diffusion technique and E-test method. 
In the absence of a reference zone size for V. chol-
erae resistance to erythromycin and azithromy-
cin, we used the zone size for other organisms 
to determine the susceptibility (zone of inhibi-
tion ≥23 mm for erythromycin and ≥18 mm for 
azithromycin) of the V. cholerae strains to these 
drugs. Seventeen of the 35 (49%) V. cholerae 
strains were resistant to both erythromycin and 
azithromycin, while the remaining 18 (51%) 
strains were susceptible to both erythromycin and 
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Sir,
Cholera is endemic and follows a distinct sea-
sonality in Bangladesh (1). Early administration 
of rehydration therapy using appropriate oral or 
intravenous fluid(s) saves the lives of patients 
with cholera. Therapy with an effective antimi-
crobial agent significantly shortens the dura-
tion of diarrhoea and hospitalization, reduces the 
volume of watery stool and the requirement of 
maintenance fluids, and shortens the duration 
of faecal excretion of Vibrio cholerae reducing 
transmission of infection to other family mem-
bers and nosocomial infections in the clinic set-
ting (2). 
Tetracycline and doxycycline (long-acting tetra-
cycline) have long been the antibiotics of choice 
for treating severe cholera in Bangladesh and in 
other parts of the world, except for young chil-
dren and pregnant women (1,2). Furazolidone, 
erythromycin, trimethoprim-sulphamethoxazole, 
and chloramphenicol have also been effective 
in treating severe cholera caused by strains of V. 
cholerae susceptible to these agents (3).
During October 2004–December 2005, 953 (565 
Ogawa and 388 Inaba) and 344 (197 Ogawa and 
147 Inaba) strains of V. cholerae O1 isolated from 
cholera cases admitted to the Dhaka Hospital 
(urban area) and Matlab Hospital (rural area) of 
ICDDR,B  respectively  were  examined  for  sus-
ceptibility to tetracycline, erythromycin, trime-
thoprim-sulphamethoxazole, furazolidone, and 
ciprofloxacin.  Antimicrobial  susceptibility  was 
performed using the disc-diffusion technique on 
Mueller-Hinton agar (Difco, Detroit, Michigan, 
USA) with commercial discs (Oxoid, UK) and ap-
propriate control strains (4). Faruque ASG et al. Multidrug-resistant Vibrio cholerae O1
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azithromycin. The strains resistant to erythro-
mycin exhibited minimum inhibition concen-
trations (MICs) of 8 to 32 µg/mL, while the MIC 
of  those  susceptible  to  the  drug  ranged  from 
0.25 to 1 µg/mL. The MIC of the strains resistant 
to azithromycin ranged from 0.75 to 3 µg/mL, 
while the MIC of those susceptible to the drug 
was from 0.047 to 0.125 µg/mL. These findings 
suggest that resistance to erythromycin could 
be a marker for resistance to azithromycin. 
Similarly, resistance to tetracycline is considered 
a proxy indicator for resistance to doxycycline 
(5). We have, for the first time, encountered this 
unique, multidrug-resistant pattern, including 
resistance to erythromycin, among V. cholerae O1 
in Bangladesh.
Throughout the period of this investigation, all 
isolates from Matlab and Dhaka were susceptible 
to ciprofloxacin. The MIC for ciprofloxacin was 
determined using E-test (AB-BIODISK, Sweden) 
with the zone size interpretive criteria for sus-
ceptibility corresponding to 0.06 µg/mL (5). We 
noted a consistent increase in the median MIC 
of V. cholerae O1 strains isolated at the Dhaka 
Hospital over the years: 0.003 µg/mL in 1994, 
0.023 µg/mL in 2001, and 0.38 to 0.5 µg/mL in 
2005 (6,7). In a recent study in adults infected 
with V. cholerae O1, we observed clinical success 
(resolution of diarrhoea by 48 hours of initia-
tion of therapy) rate of 68% with 500-mg 12-
hourly dose of ciprofloxacin for three days—a 
rate substantially lower than that observed with 
a single one-gramme dose of the drug in an ear-
lier study (8). 
The findings are disturbing since a further in-
crease in the MIC may render ciprofloxacin in-
effective in the management of cholera caused 
by  such  multidrug-resistant  strains  of  V.  chol-
erae O1. Further studies are being conducted at 
ICDDR,B to determine the mechanism of resis-
tance of these multidrug-resistant strains to cip-
rofloxacin. 
In August 2006, we observed a re-emergence of 
the Inaba serotype and a sharp reduction in the 
isolation rate of the Ogawa serotype. In Bangla-
desh, such changes in serotypes and the appear-
ance of short-lasting, multidrug-resistance, have 
also been noted in the past (9,10,11). The pro-
portion of V. cholerae strains resistant to tetracy-
cline decreased substantially (from 75% in Janu-
ary 2006 to 10% in August 2006). Resistance to 
tetracycline persisted for nearly two years, a find-
ing that we have not observed earlier (12,13).
The current situation clearly demonstrates the 
need to monitor MIC in areas where cholera is 
endemic to assess the clinical efficacy of cipro-
floxacin in the treatment of cholera. There is also 
a need to identify effective alterative antimicro-
bials for the management of cholera caused by 
such strains. Through this communication, we 
would also like to alert our neighbouring coun-
tries and the region of circulation of this new 
multidrug-resistant strain of V. cholerae O1. 
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Fig. Resistance patterns of V. cholerae O1 in Dhaka and Matlab by month and site
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